AR (Androgen receptor)

This rare synchronous pathology illustrates the signifi cant heterogeneity of neoplasia associated withCAIS. Current evidence supports individualized postpubertal gonadectomy to balance the risk of malignancy againstthe benefi ts of endogenous hormonal production. The fi ndings emphasize that long-term follow-up and tailoredsurgical timing are essential components in the clinical management of CAIS.

In AR-positive cells, CREB5 overexpression promoted cell colony growth with tumorigenic properties and increased tumor size in vivo. These findings implicate CREB5 as a driver of the transcriptional programs underlying AR-independent basal and SCL CRPC subtypes, and this activity is detectable in primary PC.

Spearman correlation confirmed that anti-acne activity was positively correlated with synergistic effects of caffeic acid and 6,7-dihydroxycoumarin. In summary, Viola philippica extract exhibits promising multi-target anti-acne potential, supporting its development as a novel multifunctional treatment strategy.

Notably, WCF-598 also exhibited a secondary activity by degrading androgen receptor splice variant 7 (AR-V7), a clinically relevant driver of therapy resistance in CRPC. These results establish WCF-598 as a specific chemical probe for investigating the function of RXRγ in CRPC and potentially other RXRγ-related diseases.

Moreover, TMP restored the fertility index and promoted embryo implantation, comparable to control animals. In conclusion, Thai Mucuna pruriens seed extract, particularly at 300 mg/kg, effectively reversed the reproductive, endocrine, and fertility impairments in letrozole-induced PCOS animal model, suggesting its promising potential as a phytotherapeutic agent for managing PCOS-associated reproductive dysfunction.

Functionally, RBM15 overexpression reduces PCa cell sensitivity to enzalutamide, whereas its knockdown suppresses tumor growth and invasion...Collectively, our findings establish RBM15 as a central epitranscriptomic driver of CRPC and identify the RBM15-DDB1-AR axis as a promising therapeutic target. Dual inhibition of RBM15 and AR may offer a novel strategy to overcome treatment resistance in advanced PCa.

In this study, AR status showed no association with DFS, BCSS, or OS; and was not a prognostic factor in TNBC. Further studies exploring the role of AR in TNBC are warranted as AR expression could be a potential target with antiandrogen therapy.

P2, N=57, Completed, National Cancer Center Hospital East | Active, not recruiting --> Completed

P3, N=142, Recruiting, Ente Ospedaliero Ospedali Galliera

Myricetin treatment also exhibited anti-proliferative and anti-angiogenic effects, as evidenced by the reduced prostatic proliferating cell nuclear antigen (PCNA) and vascular endothelial growth factor-A (VEGF-A) mRNA expression levels. In summary, myricetin displays potential as a BPH therapy by diminishing inflammation and oxidative stress, hindering 5-α reductase/AR/DHT signaling, and endorsing pro-apoptotic over anti-apoptotic pathways.

Preclinical targeting of this axis suggested a potential therapeutic strategy, as suppressed tumor growth in prostate cancer xenograft was observed following LF knockdown coupled with ferroptosis induction (via IKE) and androgen receptor inhibition (via enzalutamide). This work defines lactoferrin as: (i) an AR-regulated ferroptosis suppressor, (ii) a regulator of prostate cancer's "iron addiction," and (iii) a candidate target for therapeutic exploitation of iron-metabolic vulnerability.

Given the rarity of the tumor, it is crucial to distinguish it from morphological mimics to inform appropriate patient management. Treatment approaches are typically based on protocols for primary breast cancer, given the histological and biological similarities between these tumors and breast tissue.